Patents Assigned to Takeda Pharmaceutical Company Limited
  • Purification of factor VIII subspecies
    Patent number: 11299533
    Abstract: The present invention relates to a method for purifying a Factor VIII (FVIII) subspecies from a composition comprising FVIII, said method comprising an anion exchange chromatography step, a size exclusion chromatography step, and a concentration step. The invention also relates to a composition comprising a purified FVIII subspecies.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: April 12, 2022
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Meinhard Hasslacher, Martin Feichtinger, Philipp M. Bärnthaler, Christa Mayer, Birgit Reipert, Mantas Malisauskas, Julia Anzengruber
  • Anti-plasma kallikrein antibodies
    Patent number: 11299553
    Abstract: Disclosed herein are antibodies capable of binding to plasma kallikrein and inhibit its activity. Such antibodies interact with one or more critical residues in the catalytic domain of the plasma kallikrein. The antibodies may also contain specific heavy chain complementarity determining region 3 (CDRs) motifs and optionally specific residues at certain positions within both the heavy chain variable region and the light chain variable region.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: April 12, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Andrew Nixon, Jon A. Kenniston, Stephen R. Comeau
  • Substituted piperidine compound and use thereof
    Patent number: 11292766
    Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: April 5, 2022
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Tatsuhiko Fujimoto, Kentaro Rikimaru, Koichiro Fukuda, Hiromichi Sugimoto, Takahiro Matsumoto, Norihito Tokunaga, Mariko Hirozane
  • HETEROCYCLIC COMPOUND
    Publication number: 20220098180
    Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.
    Type: Application
    Filed: January 29, 2020
    Publication date: March 31, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Masahiro ITO, Takeshi YAMAMOTO, Keiko KAKEGAWA, Hideyuki SUGIYAMA, Tohru MIYAZAKI, Yasuyoshi ARIKAWA, Tomohiro OKAWA, Jinichi YONEMORI, Osamu KUBO, Akinori TOITA, Takuto KOJIMA, Fumiaki KIKUCHI, Minoru SASAKI, Misaki HOMMA, Yasuhiro IMAEDA, Hironobu MAEZAKI, Shiinobu SASAKI, Ayumu SATO, Hirotaka KAMITANI, Yasutomi ASANO, Hironori KOKUBO, Masato YOSHIKAWA
  • METHOD FOR DETECTING CELLS
    Publication number: 20220099670
    Abstract: Disclosed is a method for detecting regulatory dendritic cells, the method comprising step a: detecting the presence or absence of one or more types of molecules on a cell surface in a cell population that comprises regulatory dendritic cells; and step b: identifying regulatory dendritic cells on the basis of the presence or absence of the one or more types of molecules. Also disclosed is a method for producing a cell population enriched for regulatory dendritic cells, the method comprising step 1: detecting the presence or absence of one or more types of molecules on a cell surface in a cell population that comprises regulatory dendritic cells; and step 2: obtaining a cell population enriched for regulatory dendritic cells on the basis of the presence or absence of the one or more types of molecules. Further disclosed is a cell population enriched for regulatory dendritic cells obtained by the method.
    Type: Application
    Filed: January 31, 2021
    Publication date: March 31, 2022
    Applicants: Kyoto University, TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Shin KANEKO, Shoichi IRIGUCHI, Keiko SEKIYA, Yoshiaki KASSAI
  • Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
    Patent number: 11286307
    Abstract: Provided herein are plasma kallikrein antibodies binding to active plasma kallikrein and methods of using such antibodies in treating and preventing hereditary angioedema attack, such method may involve a first treatment period and optionally, a second treatment period. Also provided are methods of using such antibodies in treating hereditary angioedema involving a single dose of the antibody to a subject who has undergone a prior HAE treatment, followed by multiple doses of the same antibody if the subject experiences an HAE attack after the single dose.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: March 29, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Burt Adelman, Yung Chyung, Jennifer Schranz
  • Treatment of CNS conditions
    Patent number: 11285139
    Abstract: Aspects of the present invention relate to a method of treating an epileptic encephalopathy in a mammal in need thereof, comprising administering a composition comprising an effective amount of (4-benzyl-4-hydroxypiperidin-1-yl) (2,4?-bipyridin-3-yl)methanone or a pharmaceutically acceptable salt thereof to the mammal.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: March 29, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Toshiya Nishi, Shinichi Kondo
  • COMPOSITION FOR TREATING BLOOD COAGULATION AND/OR COMPLEMENT DISORDERS
    Publication number: 20220088085
    Abstract: The present invention provides a composition suitable as a composition for treating blood coagulation and/or complement disorders (raw materials for producing therapeutic agents for these diseases) and a method for effectively producing the composition. A method for producing a composition for treating blood coagulation and/or complement disorders according to the present invention includes the following steps of: (1) embedding an organoid formed from vascular endothelial cells or vascular endothelial cells and hepatocytes, in an extracellular matrix; (2) culturing the extracellular matrix; and (3) collecting a culture supernatant from the culture obtained in the step (2).
    Type: Application
    Filed: February 27, 2020
    Publication date: March 24, 2022
    Applicants: Public University Corporation Yokohama City University, Takeda Pharmaceutical Company Limited
    Inventors: Takanori TAKEBE, Norikazu SAIKI, Eri KAWAKAMI
  • T-CELL RECEPTOR MODIFIED OBJECT
    Publication number: 20220089672
    Abstract: The present invention provides a variant of a T-cell receptor containing a combination of two polypeptides containing a constant region of a T cell receptor chain selected from the group consisting of ? chain, ? chain, ? chain and ? chain, wherein the polypeptide does not contain a complementarity determining region (CDR) of the T cell receptor chain, a complementarity determining region (CDR) of the ? chain, and a complementarity determining region (CDR) of the ? chain.
    Type: Application
    Filed: December 26, 2019
    Publication date: March 24, 2022
    Applicants: Kyoto University, Takeda Pharmaceutical Company Limited
    Inventors: Shin KANEKO, Yoshiaki KASSAI, Akira HAYASHI
  • HETEROCYCLIC COMPOUND AND USE THEREOF
    Publication number: 20220089525
    Abstract: A heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like is provided. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
    Type: Application
    Filed: January 23, 2020
    Publication date: March 24, 2022
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Yuya OGURO, Makoto KAMATA, Satoshi MIKAMI, Shinji MORIMOTO, Sachie TAKASHIMA, Masaki DAINI, Osamu KUBO, Fumiaki KIKUCHI, Akinori TOITA, Florian PUENNER, Takahito KASAHARA, Masataka MURAKAMI, Shuhei IKEDA, Fumie YAMAGUCHI, Minoru NAKAMURA, Takafumi YUKAWA
  • Heterocyclic compound and use thereof
    Patent number: 11279713
    Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: March 22, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masakuni Kori, Toshihiro Imaeda, Shinji Nakamura, Masashi Toyofuku, Eiji Honda, Yasutomi Asano, Osamu Ujikawa, Michiyo Mochizuki
  • SUBCUTANEOUS ADMINISTRATION OF ADAMTS13
    Publication number: 20220080032
    Abstract: This invention relates to methods of subcutaneous administration of ADAMTS13 formulations to a treat a disease or condition associated with ADAMTS13 and VWF dysfunction. Furthermore, evidence of the unexpectedly high bioavailability of ADAMTS13 formulations administered subcutaneously is provided herein.
    Type: Application
    Filed: November 12, 2021
    Publication date: March 17, 2022
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Alexandra Nathalie KOPIC, Werner HOELLRIEGL, Barbara PLAIMAUER, Hanspeter ROTTENSTEINER, EVA-Maria MUCHITSCH
  • SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF
    Publication number: 20220081399
    Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.
    Type: Application
    Filed: January 21, 2021
    Publication date: March 17, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko FUJIMOTO, Kentaro RIKIMARU, Koichiro FUKUDA, Hiromichi SUGIMOTO, Takahiro MATSUMOTO, Norihito TOKUNAGA, Mariko HIROZANE
  • Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in Crohn's disease
    Patent number: 11273182
    Abstract: Provided herein are expanded allogeneic adipose tissue-derived stromal stem cells for use in treating complex perianal fistulas in Crohn's Disease.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: March 15, 2022
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Eduardo Bravo, Maria Pascual
  • Heterocyclic compound
    Patent number: 11274101
    Abstract: The present invention provides a compound having an MAGL inhibitory action, and expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: March 15, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Makoto Kamata, Hideyuki Sugiyama, Minoru Nakamura, Masataka Murakami, Shuhei Ikeda, Tomohiro Okawa, Hidekazu Tokuhara
  • ANTI-FACTOR IX PADUA ANTIBODIES
    Publication number: 20220056150
    Abstract: Provided herein are anti-Factor IX Padua binding constructs, e.g., antibodies and antigen-binding fragments thereof. Related polypeptides, conjugates and kits are also provided. The inventions may be used in methods of detecting Factor IX Padua in a sample.
    Type: Application
    Filed: August 17, 2021
    Publication date: February 24, 2022
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Dirk VOELKEL, Robert PACHLINGER, Hanspeter ROTTENSTEINER, Alfred WEBER, Andrea ENGELMAIER
  • INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF
    Publication number: 20220056028
    Abstract: Provided herein are compounds that inhibit pKal, a serine protease whose activity is responsible for proteolytically cleaving kininogen and generating the potent vasodilator and pro-inflammatory peptide bradykinin, which can lead to painful and debilitating inflammatory attacks (e.g., edema). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating pKal-related diseases and disorders (e.g., edema) with the compounds in a subject, by administering the compounds and/or compositions described herein.
    Type: Application
    Filed: November 4, 2021
    Publication date: February 24, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Jeremy Travins, Thomas Miller, Nikolaos Papaioannou
  • Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A
    Patent number: 11254731
    Abstract: The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor VIII variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia A.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: February 22, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Falko-Günter Falkner, Franziska Horling, Johannes Lengler, Hanspeter Rottensteiner, Friedrich Scheiflinger
  • ADAMTS13 protein cell culture supernatant
    Patent number: 11254921
    Abstract: The present invention provides culture mediums that are useful for the expression of ADAMTS proteins, such as ADAMTS13. Methods for the expression and purification of ADAMTS proteins are also provided. In some embodiments, the mediums and methods of the invention are useful for the expression of ADAMTS proteins having high specific activities. Also provided are ADAMTS, e.g., ADAMTS13, protein compositions with high specific activities, which are expressed and purified according to the methods provided herein.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: February 22, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Leopold Grillberger, Alexandra Spenger, Meinhard Hasslacher, Rana Grillberger, Manfred Reiter
  • USE OF ADAMTS13 FOR TREATING, AMELIORATING AND/OR PREVENTING VASO-OCCLUSIVE CRISIS IN SICKLE CELL DISEASE, ACUTE LUNG INJURY AND/OR ACUTE RESPIRATORY DISTRESS SYNDROME
    Publication number: 20220047688
    Abstract: The disclosure provides compositions and methods for treating, ameliorating, and/or preventing a vaso-occlusive crisis (VOC) in a subject suffering from sickle cell disease (SCD). The disclosure also provides compositions and methods for treating, ameliorating, and/or preventing lung injury in a subject suffering from or at risk of suffering from acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS). The disclosure provides A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, member-13 (ADAMTS13) or a composition comprising ADAMTS13 for treating, ameliorating, and/or preventing the VOC, or for treating, ameliorating, and/or preventing lung injury in a subject suffering from or at risk of suffering from ALI and/or ARDS.
    Type: Application
    Filed: November 1, 2021
    Publication date: February 17, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Bruce EWENSTEIN, Brahm GOLDSTEIN, Bernhard MAJER, Paolo ROSSATO, Friedrich SCHEIFLINGER, Marietta TURECEK